 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

SAN DIEGO, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak platform to develop drug-Fc conjugate (DFC...

Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak platform to develop drug-Fc conjugate (DFC...

Cidara Therapeutics to Present New Data on Novel drug-Fc conjugate CD388 at IDWeek 2023

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Cidara Therapeutics to host virtual research and development day

Cidara Therapeutics, Inc. (NASDAQ:CDTX  Get Free Report) insider Leslie Tari sold 18,469 shares of the companys stock in a transaction dated Monday, September 11th. The shares were sold...

Insider Selling: Cidara Therapeutics, Inc. (NASDAQ:CDTX) Insider Sells 18,469 Shares of Stock

Insider Sell: Chief Scientific Officer Leslie Tari Sells 18,469 Shares of Cidara Therapeutics Inc

Update on Phase 2a data for JNJ-0953 (CD388) for universal prevention of seasonal influenza from Janssen Pharmaceuticals, Inc. leadership following Election to Proceed notification Detailed...

Cidara Therapeutics to Host Virtual Research & Development Day on its Cloudbreak  Development Pipeline on September 21, 2023

Decision follows promising interim efficacy and safety data from ongoing Phase 1 and 2a trials Cidara to receive a $7 million milestone payment and is eligible to receive an additional $685 million...

Cidara Therapeutics Announces Janssen s Election to Proceed Under its License Agreement Relating to Novel Drug-Fc Conjugates Targeting Influenza

SAN DIEGO, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company using its proprietary Cloudbreak platform to develop drug-Fc conjugate (DFC...

Cidara to Present at the 25th Annual H.C. Wainwright Global Investment Conference

Dr. Davarpanah will lead Cidaras oncology efforts, focusing on strategy to advance development candidates Previously served as Clinical and Translational Lead in Oncology at Genentech/Roche SAN DIEGO, Aug. 16, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company...

Cidara Therapeutics Announces Appointment of Nicole Davarpanah, M.D., J.D., as Senior Vice President of Translational Research & Development

Cidara Therapeutics, Inc. (NASDAQ:CDTX  Free Report)  Equities research analysts at HC Wainwright issued their Q1 2024 EPS estimates for Cidara Therapeutics in a report issued on Monday, August 7th. HC Wainwright analyst E. Arce forecasts that the biotechnology company will post ...

Research Analysts Issue Forecasts for Cidara Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:CDTX)

Cidara Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, and commercialization of therapeutics for patients facing serious diseases, specifically oncology and infectious diseases. Its product pipeline includes Rezafungin Acetate and Cloudbreak. The company was founded by Kevin M. Forrest, Kevin J. Judice, and H. Shaw Warren in December 2012 and is headquartered in San Diego, CA.

Watchers	8,461
52-Wk Low	$0.4601
52-Wk High	$2.10

Market Cap	$83.03M
Volume (M)	312,265.00
52-Wk High	$2.10
52-Wk Low	$0.4601

CDTX Cidara Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals